Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Strategic Investment Advisors MI

Strategic Investment Advisors MI lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 5.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,605 shares of the company’s stock after buying an additional 360 shares during the period. Strategic Investment Advisors MI’s holdings in Novo Nordisk A/S were worth $654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in shares of Novo Nordisk A/S by 8.4% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 7,453 shares of the company’s stock worth $641,000 after purchasing an additional 578 shares during the period. Stablepoint Partners LLC boosted its position in shares of Novo Nordisk A/S by 5.2% during the 4th quarter. Stablepoint Partners LLC now owns 12,068 shares of the company’s stock worth $1,038,000 after purchasing an additional 600 shares during the period. Novare Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 25.6% during the 4th quarter. Novare Capital Management LLC now owns 3,424 shares of the company’s stock worth $295,000 after purchasing an additional 697 shares during the period. Embree Financial Group purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $1,210,000. Finally, KFG Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 14.9% during the 4th quarter. KFG Wealth Management LLC now owns 4,821 shares of the company’s stock worth $415,000 after purchasing an additional 626 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of research analyst reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $87.94 on Monday. The stock has a market cap of $394.65 billion, a P/E ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a fifty day simple moving average of $95.35 and a 200-day simple moving average of $114.99. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.